Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) has received a consensus recommendation of “Hold” from the eight analysts that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $73.83.
Several equities analysts have issued reports on the stock. Zacks Investment Research cut shares of Vir Biotechnology from a “buy” rating to a “hold” rating in a research note on Thursday, March 3rd. TheStreet cut shares of Vir Biotechnology from a “c-” rating to a “d+” rating in a research note on Monday, March 28th. Robert W. Baird upgraded shares of Vir Biotechnology from an “underperform” rating to a “neutral” rating and lowered their price objective for the stock from $36.00 to $28.00 in a research note on Thursday, March 3rd. Needham & Company LLC lowered their price objective on shares of Vir Biotechnology from $80.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, March 28th. Finally, HC Wainwright lowered their price objective on shares of Vir Biotechnology from $300.00 to $200.00 and set a “buy” rating on the stock in a research note on Wednesday, March 30th.
Shares of Vir Biotechnology stock opened at $23.93 on Friday. The stock has a market cap of $3.17 billion, a price-to-earnings ratio of 6.17, a PEG ratio of 0.51 and a beta of -0.97. The firm’s 50-day moving average is $25.93 and its 200 day moving average is $33.86. Vir Biotechnology has a 1 year low of $20.52 and a 1 year high of $58.00.
In related news, CTO Ann M. Hanly sold 2,627 shares of the stock in a transaction that occurred on Wednesday, March 30th. The shares were sold at an average price of $26.24, for a total value of $68,932.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Vicki L. Sato sold 15,173 shares of the stock in a transaction that occurred on Tuesday, January 18th. The stock was sold at an average price of $37.39, for a total transaction of $567,318.47. The disclosure for this sale can be found here. Insiders sold a total of 51,635 shares of company stock valued at $1,744,091 over the last three months. 37.20% of the stock is currently owned by insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in VIR. Macquarie Group Ltd. purchased a new stake in Vir Biotechnology during the 3rd quarter valued at approximately $26,000. Nisa Investment Advisors LLC grew its holdings in Vir Biotechnology by 186.0% during the 4th quarter. Nisa Investment Advisors LLC now owns 1,430 shares of the company’s stock valued at $49,000 after buying an additional 930 shares in the last quarter. Canton Hathaway LLC bought a new position in shares of Vir Biotechnology during the 4th quarter valued at approximately $107,000. Dupont Capital Management Corp bought a new position in shares of Vir Biotechnology during the 4th quarter valued at approximately $174,000. Finally, Mackenzie Financial Corp bought a new position in shares of Vir Biotechnology during the 4th quarter valued at approximately $201,000. 71.47% of the stock is owned by institutional investors and hedge funds.
Vir Biotechnology Company Profile (Get Rating)
Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus.
- Get a free copy of the StockNews.com research report on Vir Biotechnology (VIR)
- Lululemon Rises On Wave Of Price Target Increases
- Is Nvidia (NASDAQ: NVDA) About To Rip Higher?
- The Top Is In For Infosys
- 3 Stellar Steel Stocks to Buy Now
- Bed Bath & Beyond Uncovers The Problem With Q1 Earnings Season
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.